Skip to content

Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat.

C W Callaway, Mark A. Geyer

European Journal of Pharmacology April 7, 1992 DOI: 10.1016/0014-2999(92)90094-k (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study Peer reviewed
Population Rats
Interventions S-amphetamine MBDB
Topics MDMA
Citations 35
Key findings S-MDMA injected into the nucleus accumbens produces locomotor hyperactivity that is not blocked by fluoxetine, indicating its action there is via catecholamine release rather than serotonin release.

Abstract

This study examined the behavioral effects in rats of intracerebral administration of S(+)-3,4-methylenedioxymethamphetamine (S-MDMA) using an automated holeboard and open-field apparatus. Administration of S-MDMA into the nucleus accumbens septi produced locomotor hyperactivity. Although the stimulant effects of S-MDMA administered systemically are antagonized by fluoxetine pretreatment, the activating effects of S-MDMA administered into the nucleus accumbens were not antagonized by fluoxetine. A similar increase in locomotor activity was observed after S-amphetamine administration into the nucleus accumbens. In contrast, the selective 5-HT-releasing drug and S-MDMA congener N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB) produces MDMA-like locomotor hyperactivity when administered systemically but did not alter locomotor activity when injected into the nucleus accumbens. These data indicate that S-MDMA actions in the nucleus accumbens are pharmacologically distinct from the primary effects of systemically administered S-MDMA. Behavioral effects of S-MDMA in the nucleus accumbens may result from the catecholamine-releasing properties that S-MDMA shares with S-amphetamine and not via the 5-HT-releasing properties that it shares with MBDB.